<tj class="koxljrj"></tj>

AG贵宾会

Be the most trusted biotech company

2019-12-31

First Patient Dosed in Phase 2 Study of Henlius Innovative Anti-PD-1 Monoclonal Antibody HLX10 for the Treatment of Chronic Hepatitis B
2019-12-13

First Patient Dosed in Phase 3 Clinical Trial of Anti-PD-1 mAb HLX10 in Combination with Bevacizumab Biosimilar HLX04 in Patients with Metastatic nsNSCLC
2019-12-13

First Patient Dosed in Phase 3 Study of Anti-PD-1 mAb in Combination with Chemotherapy in Neo-/Adjuvant Treatment for Patients with Gastric Cancer
2019-12-09

The Anti-PD-1 mAb Combined with Anti-EGFR mAb Therapy of Henlius Received Approvals to Conduct Clinical Trials by NMPA
2019-12-09

First China Approved Rituximab Biosimilar HLX01: Pharmacokinetics, Safety and Efficacy Comparison to Reference Rituximab in the Phase 3 DLBCL Study
2019-12-05

Henlius and FARMA DE COLOMBIA Enter into Exclusive License Agreement for Rituximab HLX01
2019-11-27

A Novel Anti-PD-1 Antibody HLX10 Study Led to the Initiation of Combination Immunotherapy
2019-11-27

A Novel Anti-EGFR Antibody HLX07 for Potential Treatment of Squamous Cell Carcinoma of the Head and Neck
2019-11-26

First China-Manufactured Trastuzumab Biosimilar HLX02 Global Phase 3 Trial Met Primary Endpoint in Breast Cancer

1
2
3
4